Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtronic v. Boston Scientific

This article was originally published in The Gray Sheet

Executive Summary

Federal court in Marshall, Texas, finds that two of the three Medtronic patents allegedly infringed upon by certain Boston Scientific balloon angioplasty catheters and stent delivery systems are unenforceable due to "inequitable conduct" by Medtronic, Boston Scientific announces Aug. 29. A jury previously found that 10 of the Boston Scientific devices infringed Medtronic's Anderson and Fitzmaurice patents, and awarded $250 million in damages, later reduced to $186 million (1"The Gray Sheet" June 2, 2008, p. 16). As a result of the Aug. 29 decision, the damages were further reduced to $19 million. However, Boston Scientific says it plans to appeal the award in Washington, D.C., federal appeals court. Medtronic also says it is evaluating an appeal
Advertisement

Related Content

Medtronic Awarded $250 Mil., May Seek Injunction On Boston Sci Catheters
Medtronic Awarded $250 Mil., May Seek Injunction On Boston Sci Catheters
Advertisement
UsernamePublicRestriction

Register

MT026517

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel